1. A pharmaceutical composition for treating acute renal failure caused by rhabdomyolysis comprising a therapeutically effective amount of HGF and a pharmaceutically acceptable carrier.
2. A pharmaceutical composition for treating myoglobinuria comprising a therapeutically effective amount of HGF and a pharmaceutically acceptable carrier.
3. A pharmaceutical composition for treating acute renal failure caused by rhabdomyolysis caused by a myolytic substance released by external injury, compression damage, crash syndrome, burn, infection, drug poisoning, muscle metabolic disease, overuse of muscle, hypophosphatemia, or snake venom comprising a therapeutically effective amount of HGF.
4. A method of treating acute renal failure caused by rhabdomyolysis comprising administering a therapeutically effective amount of HGF to a patient in need thereof.
5. A method of treating myoglobinuria comprising administering a therapeutically effective amount of HGF to a patient in need thereof.
6. A method of treating acute renal failure caused by rhabdomyolysis caused by a myolytic substance released by external injury, compression damage, crash syndrome, burn, infection, drug poisoning, muscle metabolic disease, overuse of muscle, hypophosphatemia, or snake venom comprising administering a therapeutically effective amount of HGF to a patient in need thereof.
7. A packaged product, comprising:
a container;
HGF contained within said container in an amount therapeutically effective for treating acute renal disease caused by rhabdomyolysis or myoglobinuria; and
instructions associated with said container which indicate that said HGF can be used for treating acute renal disease caused by rhabdomyolysis or myoglobinuria.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A titanium dioxide nanoparticle having a quasicrystalline phase corresponding to an intermediate form between a crystalline phase and an amorphous phase.
2. The titanium dioxide nanoparticle of claim 1, wherein
a main XRD peak of the quasicrystalline phase is shifted and broadened as compared to the crystalline phase.
3. The titanium dioxide nanoparticle of claim 2, wherein
the quasicrystalline phase has a full width at half maximum (FWHM) of 1.9 to 2.5.
4. The titanium dioxide nanoparticle of claim 2, wherein
the main x-ray diffraction (XRD) peak of the quasicrystalline phase is shifted as compared to a main peak of an anatase crystalline phase, such that satisfies the following equation: 23\xb0\u22662\u03b8\u226626\xb0.
5. The titanium dioxide nanoparticle of claim 2, wherein
the main x-ray diffraction (XRD) peak of the quasicrystalline phase is shifted as compared to a main peak of a rutile crystalline phase, such that 2\u03b8 satisfies the following equation: 26\xb0\u22662\u03b8\u226629\xb0.
6. The titanium dioxide nanoparticle of claim 1, wherein
the particles have an average particle size of 150 nm or less.
7. A preparation method of titanium dioxide nanoparticles, the preparation method comprising:
a) mixing a TiCl4 solution and water to prepare TiOCl2 in a jelly form; and
(b) obtaining titanium dioxide nanoparticles having a quasicrystalline phase corresponding to an intermediate form between a crystalline phase and an amorphous phase through a hydrothermal reaction of mixing TiOCl2 having the jelly form with water,
wherein in step (a), an amount of water is controlled so that a concentration of Ti3+ ions becomes 0.1 to 1.3 M, and
in step (b), an amount of water is controlled so that a concentration of Ti3+ ions becomes 1.5 to 4.3 M.
8. The preparation method of claim 7, wherein
the hydrothermal reaction in step (b) is a reaction performed by heating to a temperature of 50 to 200\xb0 C.
9. A one-dimensional titanate prepared by a reaction between titanium dioxide nanoparticles having a quasicrystalline phase corresponding to an intermediate form between a crystalline phase and an amorphous phase with an alkali solution.
10. The one-dimensional titanate of claim 9, wherein
the one-dimensional titanate has a nanotube, a nanosheet, a nanowire, or a nanorod shape.
11. A preparation method of titanate, the preparation method comprising reacting the titanium dioxide nanoparticles prepared by the preparation method of claim 7 with a 5 M to 25 M aqueous alkali solution to obtain one-dimensional titanate.
12. The preparation method of claim 11, wherein:
the aqueous alkali solution contains at least one of LiOH, KOH, and NaOH.
13. The preparation method of claim 11, wherein
the reaction between the titanium dioxide nanoparticles and the aqueous alkali solution is performed at 80 to 350\xb0 C. for 6 to 20 hours.
14. A lithium titanate nanoparticle prepared by a reaction between the one-dimensional titanate of claim 9 and lithium hydroxide (LiOH).
15. A preparation method of lithium titanate nanoparticles comprising reacting titanate prepared by the preparation method of claim 11 with 10 to 30 mol of lithium hydroxide (LiOH) and heating the reactant to 400 to 1200\xb0 C.